Enhanced Manufacturing Efforts by Sanofi and AstraZeneca Aim to Prevent Beyfortus Shortfalls in 2024

Beyfortus Approval and Use:
Beyfortus (nirsevimab-alip) is a long-acting monoclonal antibody approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Manufacturing and Supply:
Sanofi and AstraZeneca have ramped up manufacturing efforts to ensure adequate supply of Beyfortus for the 2024/2025 RSV season. This includes the approval of a new filling line by the FDA, which has expanded production capacity.

Global Availability:
Beyfortus has been approved in several countries including the European Union, the US, China, and Japan, reflecting its global reach in preventing RSV disease.

Partnership and Commercialization:
Sanofi and AstraZeneca have a collaborative agreement for the development and commercialization of Beyfortus, with AstraZeneca leading development and manufacturing activities and Sanofi leading commercialization activities and recording revenues.

Market Expectations:
Sanofi executives expect Beyfortus to achieve blockbuster status in 2024, indicating significant market potential.